TROPION-Lung07: Phase III study of Dato-DXd + pembrolizumab ± platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancer
Isamu Okamoto(Kyushu University Hospital), Aaron Lisberg(APLA Health), Ji‐Youn Han(National Cancer Centre Japan), Pongwut Danchaivijitr(Siriraj Hospital), Jong‐Mu Sun(Samsung Medical Center), Edward Pan(VA North Texas Health Care System), Natalie Ren(Daiichi Sankyo (United States)), Rajaganesh Rajagopalan(Daiichi Sankyo (United States)), Shoichi Kuyama(Iwakuni Medical Center), Fábio Franke(National Cancer Center), Shunichi Sugawara(Sendai Kousei Hospital), Nicolas Girard(Institut Curie), Ziming Li(Shanghai Jiao Tong University), A. Chen(Daiichi Sankyo (United States)), Shun Lü(Shanghai Jiao Tong University)
Cited by 20
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k